Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Perrysburg, Ohio, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ...

whose tirzepatide demonstrated a 20.9% weight loss. Viking Therapeutics (NASDAQ:VKTX)' stock soared 12% following the announcement of Novo Nordisk's disappointing obesity drug trial results.

BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...

Moreover, assumptions regarding the performance of the diabetes drug tirzepatide in 2025 will be scrutinized ... are pegged at $18.3 billion and $11.1 billion for 2025. These figures surpass consensus ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Among the data Eckel discussed were findings from the SURMOUNT-OSA trial, which assessed the impact of tirzepatide (Zepbound, Eli Lilly) on apnea-hypopnea index and body weight for adults with ...

Bruno Mars continues to break streaming records, as he becomes the first artist to cross the 150 million monthly listeners threshold on Spotify. Mars, who has not put out a solo album since 2016 ...

Enter GetSimpli Oral Tirzepatide, a revolutionary product that promises to transform your approach to weight loss and metabolic health. Unlike traditional weight loss methods that often involve ...